Welcome

Paradigm Biopharma Ltd (ASX:PAR) is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.

READ MORE

Paradigm Shift

Repurposing

Established drugs can be repurposed for new clinical indications for unmet medical needs when protected by strong intellectual property. Historical drug safety data and existing manufacturing ‘know-how’ can fast-track clinical development and reduce commercialisation costs for repurposed drugs.

READ MORE

Understanding complexity

Life is complex! For every diagnosis, there are multiple factors and biological interactions involved. We develop therapeutics targeting multiple pathways involved in injury or on the road to disease producing better outcomes for patients.

READ MORE

We develop therapeutics targeting multiple pathways involved in injury

Our focus

Pentosan Polysulphate Sodium (PPS)

We focus on PPS because this FDA approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and respiratory disease.

READ MORE

Inflammation

Inflammation is a complex biological response to injury, infection or allergy, which has short and long term components mediated by factors produced by immune cells.

READ MORE

Recent Highlights

Click here for all ASX announcements.

Paradigm phase 2B trial meets key secondary endpoints in Osteoarthritis of the knee

15th April 2019

Key highlights: Phase 2B clinical trial subjects receiving injectable pentosan polysulfate sodium were shown to have: improved knee function for 6 months; durable pain reduction for 6 months and …

READ MORE

Paradigm launches a A$77.9 million capital raise comprising a $51.5 million placement and a $26.3 million underwritten accelerated entitlement offer to fund the company's clinical trial program

15th April 2019

Paradigm launches a A$77.9 million capital raise anticipated to fund the company’s OA and MPS programs through to the end of their pivotal phase 3 studies …

READ MORE

Paradigm corporate update: May 2019

8th May 2019

Paradigm Biopharmaceuticals Ltd is today pleased to provide the following update on its clinical programs and commercial progress..

READ MORE

Inflammation is a complex biological response to injury, infection or allergy

Key Statistics

Alpharirus

Alphaviruses, including Ross River virus (RRv) and Chikungunya (CHIKV) are mosquito-transmitted arthritogenic alphaviruses that cause epidemics of severe musculoskeletal disease.

*Simon, Fabrice et al. “Chikungunya Virus Infection.” Current Infectious Disease Reports 13.3 (2011): 218–228. PMC. Web. 10 Oct. 2016

Osteoarthritis (OA)

OA is a condition with a significant unmet medical need. Opioid abuse resulting from mismanagement of pain is a major problem in the US and most western countries.

*National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011 September

Bone Marrow Edema (BME)

Worldwide hip & knee surgical implant market is $16.7 billion, will be $33 billion by 2022. Acute joint injury leads to osteoarthritis.

Bone Marrow Edema (BME)

>50% top ranked skiers have injured knee ligaments (women 5x more susceptible than men)

Company Pipeline

Research & Development

Paradigm is evaluating new intellectual property that has relevance to treating inflammation, especially in orthopaedics.

READ MORE